Effects of Chemotherapeutic Agents on the Immune Response. II

References

• Berenbaum M C. The clinical pharmacology of immunosuppressive agents. Clinical Aspects of Immunology, R RA Gell, Pgh, Coombs, P J Lachmann. Blackwell Scientific Publications, Oxford 1975; 689–758
   Google Scholar
• Bach J F. Immunosuppression. Renal Transplantation-Theory and Practice, J Hamburger, J Crosnier, J F Bach, H Kreis. Williams and Wilkins, Baltimore 1981; 89–145
   Google Scholar
• Burchenal J H, Bendich A, Brown G B, et al. Preliminary studies on the effect of 2, 6-diaminopurine on transplanted mouse leukemia. Cancer 1949; 2: 119–120
   PubMed Web of Science ®Google Scholar
• Schwartz R S, Stack J D, Dameshek W. Effect of 6-mercap-topurine on antibody production. Proc Soc Exp Biol Med 1958; 99: 164–170
   PubMed Web of Science ®Google Scholar
• Elion G B, Callahan S, Bieber S, Hitchings G H, Rundles R W. A summary of investigations with 2-amino-6-[methyl-4-nitro-5-imidazolythio] purine (B.Z. 57–322). Cancer Chemother Pharmacol 1961; 14: 93–98
   Google Scholar
• Elion G B. Biochemistry and pharmacology of purine analogues. Fed Proc Am Soc Exp Biol 1967; 26: 898–904
   PubMedGoogle Scholar
• Elion G B. The comparative metabolism of “imuran” and 6-mercaptopurine (6-MP) in man. Proc Am Assoc Cancer Res 1969; 10: 21
   Web of Science ®Google Scholar
• Berenbaum M C. Time dependence and selectivity of immunosuppressive agents. Immunology 1979; 36: 355–365
   PubMed Web of Science ®Google Scholar
• Schwartz R S. Specificity of immunosuppression by antimetabolites. Fed Proc 1966; 25: 165–168
   PubMedGoogle Scholar
• Chanmougan D, Schwartz R S. Enhancement of antibody synthesis by 6-mercaptopurine. J Exp Med 1966; 124: 363–378
   PubMed Web of Science ®Google Scholar
• Frisch A W, Davies G H. The inhibition of hemagglutinin formation in mice by purine and pyrimidine analogues. J Immunol 1962; 88: 269–273
   PubMed Web of Science ®Google Scholar
• Mannick J A, Lee H M, Egdahl R H. The effect of 6-mercaptopurine on immune responsiveness of the dog. Surg Gyn Obs Int Abstr Surg 1962; 114: 449–457
   PubMedGoogle Scholar
• Levin R H, Landy M, Frei E, III. The effect of 6-mercaptopurine on immune response in man. New Engl J Med 1964; 271: 16–22
   PubMed Web of Science ®Google Scholar
• Genhof D A, Battisto J R. Antibody production in guinea pigs receiving 6-mercaptopurine. Proc Soc Exp Biol Med 1961; 107: 933–936
   PubMed Web of Science ®Google Scholar
• Maibach H I, Maguire H C. Studies on the inhibition of antibody formation in the guinea pig with cyclophosphamide, azathioprine, 5-fluorouracil, and urethane. Int Arch Allergy Appl Immunol 1966; 29: 209–212
   Google Scholar
• Berenbaum M C. The action of antimitotic substances on the immune response. Pathol Biol 1961; 9: 963–966
   Google Scholar
• Sahiar K, Schwartz R S. The immunoglobulin sequence. I. Arrest by 6-mercaptopurine and restitution by antibody, antigen or splenectomy. J Immunol 1965; 95: 345–354
   PubMed Web of Science ®Google Scholar
• Spreafico F, Donelli M G, Bossi A, et al. Immunodepressant activity of 6-mercaptopurine and azathioprine. Transplantation 1973; 16: 269–278
   PubMed Web of Science ®Google Scholar
• Page A R, Condie R M, Good R A. Effect of 6-mercaptopurine on inflammation. Am J Pathol 1962; 40: 519–530
   PubMed Web of Science ®Google Scholar
• Kimball A P, Herriot S J, Allison P S. Studies on immunosuppressive drugs. Proc Soc Exp Biol Med 1967; 126: 181–184
   PubMed Web of Science ®Google Scholar
• Calne R Y. Inhibition of the rejection of renal homografts in dogs by purine analogues. Transplant Bull 1961; 28: 445–461
   Google Scholar
• Murray J E, Sheil A GR, Moseley R, et al. Analysis of the mechanism of immunosuppressive drugs in renal homo-transplantation. Ann Surg 1964; 160: 449–473
   PubMed Web of Science ®Google Scholar
• Hurd E R, Ziff M. Studies on the anti-inflammatory action of 6-mercaptopurine. J Exp Med 1968; 128: 785–800
   PubMed Web of Science ®Google Scholar
• Vogel C L, Calabresi P. Enhanced suppression of experimental allergic encephalomyelitis by combination chemotherapy with duazomycin-A and 6-mercaptopurine. Proc Soc Exp Biol Med 1969; 131: 251–256
   PubMed Web of Science ®Google Scholar
• Hersh E M, Oppenheim J J. Inhibition of in vitro lymphocyte transformation during chemotherapy in man. Cancer Res 1967; 27: 98–105
   PubMed Web of Science ®Google Scholar
• Merritt K, Johnson A G. Studies on the adjuvant action of bacterial endotoxin on antibody formation. V. The influence of endotoxin and 5-fiuoro-2′-deoxyuridine on the primary antibody response of the BALB mouse to a purified protein antigen. J Immunol 1963; 91: 266–272
   PubMed Web of Science ®Google Scholar
• Blomgren S E, Wolberg W H, Kisken W A. Effect of fluo-ropyrimidines on delayed cutaneous hypersensitivity. Cancer Res 1965; 25: 977–979
   PubMed Web of Science ®Google Scholar
• Mitchell M S, DeConti R C. Immunosuppression by 5-fluo-rouracil. Cancer 1970; 26: 884–889
   PubMedGoogle Scholar
• Harris J E, Hersh E M. Effect of cytosine arabinoside (CA) on the response of mice to sheep red blood cells (SRBC). Proc Am Assoc Cancer Res 1968; 9: 28
   Web of Science ®Google Scholar
• Gray G D, Mickelson M M, Crim J A. The immunosuppressive activity of Ara-cytidine. I. Effects on antibody forming cells and humoral antibody. Transplantation 1968; 6: 805–817
   PubMed Web of Science ®Google Scholar
• Fischer D S, Cassidy E P, Welch A D. Immunosuppression by pyrimidine nucleoside analogs. Biochem Pharmacol 1966; 15: 1013–1022
   PubMed Web of Science ®Google Scholar
• Mitchell M S, Kaplan S R, Calabresi P. Alteration of antibody synthesis in the rat by cytosine arabinoside. Cancer Res 1969; 29: 896–904
   PubMed Web of Science ®Google Scholar
• Rollinghoff M, Schrader J, Wagner H. Clin Exp Immunol 1973; 15: 261–269
   PubMed Web of Science ®Google Scholar
• Kaplan S, Calibresi P. Suppression of delayed hypersensitivity in viro and in vitro by cytosine arabinoside. Clin Res 1965; 13: 543
   Google Scholar
• Kaplan S, Northrup J, DeConti R C, et al. Suppression of immunologic responses by cytosine arabinoside. Clin Res 1966; 14: 483
   Google Scholar
• Gray G D, Perper R J, Mickelson M M, Crim J A, Zukowski C F. The immunosuppressive activity of ARA-cytidine (Cytarabine). III. Effects of canine renal allograft rejection and hemagglutinin formation. Transplantation 1969; 7: 181–187
   Google Scholar
• Hersh E M. Immunosuppressive agents. Antineoplastic and Immunosuppressive Agents, A C Sartorelli, D G Johns. Springer, New York 1974; 576–617
   Google Scholar
• Little P A, Oleson J J, Roesch P K. The effect of pteroylglutamic acid on some immune responses of chicks. J Immunol 1950; 65: 491–498
   PubMed Web of Science ®Google Scholar
• Stevens J E, Willoughby D A. The anti-inflammatory effect of some immunosuppressive agents. J Pathol 1969; 97: 367–373
   PubMed Web of Science ®Google Scholar
• Djerassi I, Rominer C J, Kim J S, et al. Phase I study of high doses of methotrexate with citrovorum factor in patients with lung cancer. Cancer 1972; 30: 22–29
   PubMed Web of Science ®Google Scholar
• Berenbaum M C. Immunosuppressive agents. Br Med Bull 1965; 21: 140–146
   PubMed Web of Science ®Google Scholar
• Cohen S A, Royama K, Ehrke M J. Characterization of the cytotoxic effector cells (CEC) generated in the augmented in vitro primary immune response of spleen cells from mice pretreated with adriamycin (AM). Proc Am Assoc Cancer Res 1979; 731: 181
   Google Scholar
• Daddi G, Jr, Intini C, Isetta A M. Daunomycin and skin allograft survival in mice. Experentia 1970; 26: 910–911
   PubMedGoogle Scholar
• Vecchi A, Mantovani A, Tagliabue A, et al. A characterization of the immunosuppressive activity of adriamycin and daunomycin on humoral and antibody production and tumor allograft rejection. Cancer Res 1976; 36: 1222–1227
   PubMed Web of Science ®Google Scholar
• Casazza A M, DiMarco A, DiCuonzo G. Influence of daunomycin and adriamycin on the growth and regression of murine sarcoma virus (Moloney) tumors in mice. Cancer Res 1971; 31: 1971–1976
   PubMed Web of Science ®Google Scholar
• Schwartz H S, Grindey G B. Adriamycin and daunorubicin: A comparison of antitumor activities and tissue uptake in mice following immunosuppression. Cancer Res 1973; 33: 1837–1844
   PubMed Web of Science ®Google Scholar
• Giuliani F, Casazza A M, DiMarco A. Virologic and immunologic properties and response to daunomycin and adriamycin of a non-regressing mouse tumor derived from MSV-induced sarcoma. Biomed (Express) 1974; 21: 435–439
   PubMedGoogle Scholar
• Mantovani A, Polentaurutti N, Luini W, et al. Role of host defense mechanisms in the antitumor activity of adriamycin and daunomycin in mice. J Natl Cancer Inst 1979; 63: 61–66
   PubMed Web of Science ®Google Scholar
• Orsini F, Pavelic Z, Mihich E. Increased primary cell-mediated immunity in culture subsequent to adriamycin or daunorubicin treatment of spleen donor mice. Cancer Res 1977; 37: 1719–1726
   PubMed Web of Science ®Google Scholar
• Spreafico J. Hetergeneity of the interaction of anticancer agents with the immune system and its possible relevance in chemoimmunotherapy. Oncology 1980; 37(Suppl 1)9–18
   PubMedGoogle Scholar
• Orsini F R, Henderson E S. Increased developments of PHA stimulated murine colonies in vitro subsequent to adriamycin or daunorubicin treatment of spleen donor mice. Immunopharmacology 1979; 1: 203–210
   PubMedGoogle Scholar
• Mantovani A. In vitro and in vivo cytotoxicity of adriamycin and daunomycin for murine macrophages. Cancer Res 1977; 37: 815–820
   PubMed Web of Science ®Google Scholar
• Kempf R, Cebul R D, Mitchell M S. Antitumor effects of doxorubicin against a virally-induced rat osteosarcoma with minimal immunosuppression. J Immunopharmacol 1980; 2: 509–525
   PubMed Web of Science ®Google Scholar
• Roth J A, Eilber F R, Morton D L. Effect of adriamycin and high-dose methotrexate chemotherapy on in vivo and in vitro cell-mediated immunity in cancer patients. Cancer 1978; 41: 814–819
   PubMed Web of Science ®Google Scholar
• Uzema H. Bleomycin: Discovery chemistry and action. Gann 1976; 19: 3–36
   Google Scholar
• Yamaki H, Tanaka N, Umezawa H. Effects of several tumor-inhibitory antibiotics on immunologic response. J Antibiot 1969; 22: 315–321
   PubMed Web of Science ®Google Scholar
• Ohno R, Nishiwaki H, Kawashima K, et al. Lack of immunosuppressive effect of bleomycin on the primary response of mice to sheep red blood cells. Gann 1971; 62: 267–274
   PubMedGoogle Scholar
• Andrews E. An in vivo evaluation of the immunosuppressive action of bleomycin. Cancer Res 1972; 32: 1993–1994
   PubMed Web of Science ®Google Scholar
• Dlugi A M, Robie K M, Mitchell M S. Failure of bleomycin to affect humoral or cell-mediated immunity in the mouse. Cancer Res 1974; 34: 2504–2507
   PubMed Web of Science ®Google Scholar
• Lehane D E, Hurd E, Lane M. The effects of bleomycin on immunocompetence in man. Cancer Res 1975; 35: 2724–2728
   PubMed Web of Science ®Google Scholar
• Fujita H, Kimura K. Blood Level, Tissue Distribution, Excretion and Inactivation of Bleomycin. Progress in Antimicrobial and Anticancer Chemotherapy. University of Tokyo Press, Tokyo 1970; Vol 2: 309–314
   Google Scholar
• Tisman G, Herbert V, Go L T, et al. Marked immunosuppression with minimal myelosuppression by bleomycin in vitro. Blood 1973; 41: 721–726
   PubMed Web of Science ®Google Scholar
• Amiel J L, Mathe G, Matsukura M, et al. Tests for the determination of the effect of antimitotic products on immune reactions. Immunology 1964; 7: 511–526
   PubMed Web of Science ®Google Scholar
• Otte H, Grosjean O. Transplantation allogeneique de rein et conditionement de I'hote. C R Stances Soc Biol 1964; 158: 909–911
   PubMedGoogle Scholar
• Cirkovic D M, Simic M M. Effects of Actinomycin D on hemolysin formation in rats. Proceedings of the Fifth Yugoslav Conference on Radiobiology, Ljubljana, 1964, D Lebez, et al
   Google Scholar
• Broome J D. Evidence that the L-asparaginase activity in guinea pig serum is responsible for its antilymphoma effects. Nature (London) 1961; 191: 1114–1115
   Web of Science ®Google Scholar
• Beard M EJ, Crowther D, Galton D AG, et al. L-asparaginase in treatment of acute leukemia and lymphosarcoma. Br Med J 1970; 9: 191–195
   Google Scholar
• Crowther D. L-asparaginase and human malignant disease. (London) Nature 1971; 229: 168–171
   PubMed Web of Science ®Google Scholar
• Peterson R G, Handschumacher R E, Mitchell M S. Immunological responses to L-asparaginase. J Clin Invest 1971; 50: 1080–1090
   PubMed Web of Science ®Google Scholar
• Prager M D, Bachynsky N. Asparaginase synthetase in asparaginase resistant and susceptible mouse lymphomas. Bio-chem Biophys Res Commun 1968; 31: 43–47
   PubMed Web of Science ®Google Scholar
• Schwartz R S. Immunosuppression by L-asparaginase. (London) Nature 1969; 224: 275–276
   PubMed Web of Science ®Google Scholar
• Fidler I, Montgomery P C, Ferguson E. L-asparaginase and lymphocyte blastogenesis. Lancet 1971; 2: 1091–1092
   PubMed Web of Science ®Google Scholar
• Simberkoff M S, Thomas L. Reversal by L-glutamine of the inhibition of lymphocyte mitosis caused by E coli asparaginase. Proc Soc Exp Biol Med 1970; 133: 642–644
   PubMed Web of Science ®Google Scholar
• Miura M, Hirano M, Kakizawa K, et al. Inhibitory effect of L-asparaginase in lymphocyte transformation induced by phy-tohemagglutinin. Cancer Res 1970; 30: 768–772
   PubMed Web of Science ®Google Scholar
• Durden D L, Distasio J A. Comparison of the immunosuppressive effects of asparaginases from Escherichia coli and vibrio succinogenes. Cancer Res 1980; 40: 1125–1129
   PubMed Web of Science ®Google Scholar
• Ashworth L AE, MacLennan A P. Comparison of L-as-paragenases from Escherichia coli and Erwinia carotovora as immunosuppressants. Cancer Res 1974; 34: 1353–1359
   PubMed Web of Science ®Google Scholar
• Bertelli A, Donati L, Trabucchi E, Jr. Prolonged survival of alio- and xeno- grafts of skin by means of an antitumoral compound: the L-asparaginase. Arch Ital Patol Clin Tumori 1968; 11: 475–479
   PubMedGoogle Scholar
• Brambilla G, Parodi S, Cavanna M, Caraceni C E, Baldini L. The immunosuppressive activity of Escherichia coli: L-asparaginase in some transplantation systems. Cancer Res 1970; 30: 2665–2670
   PubMed Web of Science ®Google Scholar
• Schulten H K, Giraldo G, Boyse E A, Oettgen H F. Immunosuppressive action of L-asparagenase. Lancet 1969; 2: 664–665
   Google Scholar
• Fidler I J. L-asparaginase and metastases. Lancet 1970; 1: 777–778
   PubMedGoogle Scholar
• Astaldi G, Burgio G R, Krc J, et al. L-asparaginase and blastogenesis. Lancet 1969; 1: 423
   PubMed Web of Science ®Google Scholar
• Weiner M S, Waithe W I, Hirschhorn K. L-asparaginase and blastogenesis. Lancet 1969; 2: 748
   PubMed Web of Science ®Google Scholar
• Hersh E M. Immunosuppression by L-asparaginase and related enzymes. Transplantation 1971; 12: 368–376
   PubMed Web of Science ®Google Scholar
• Claman H N. Corticosteroids and lymphoid cells. New Engl J Med 1972; 287: 388–397
   PubMed Web of Science ®Google Scholar
• Germuth F G, Jr, Ottinger B. Effect of 17-Hydroxy-11-de-hydroeorticosterone (compound E) and of ACTH on Arthus reaction and antibody formation in the rabbit. Proc Soc Exp Biol Med 1950; 74: 815–823
   PubMed Web of Science ®Google Scholar
• Mirick G S. The effects of ACTH and cortisone on antibodies in human beings. Bull John Hopkins Hosp 1951; 88: 332
   PubMedGoogle Scholar
• Billingham R E, Krohn P L, Medawar P B. Effect of cortisone on survival of skin homografts in rabbits. Br Med J 1951; 1: 1157–1163
   PubMed Web of Science ®Google Scholar
• Zukoski C F, Callaway J M, Rhea W G, Jr. Prolonged acceptance of a canine renal allograft achieved with prednisone. Transplantation 1965; 3: 380–386
   PubMedGoogle Scholar
• Marchioro T L, Axtell H K, LaVia M F, et al. The role of adrenocortical steroids in reversing established homograft rejection. Surgery 1964; 55: 412–417
   PubMed Web of Science ®Google Scholar
• Fauci A D, Dale D C. Glucocorticosteroid therapy: Mechanisms of action and clinical consideration. Ann Intem Med 1976; 84: 304–315
   PubMed Web of Science ®Google Scholar
• Fauci A D, Dale D C. The effect of in vivo hydrocortisone on subpopulations of human lymphocytes. J Clin Invest 1974; 53: 240–246
   PubMed Web of Science ®Google Scholar
• Cupps T R, Fauci A S. Corticosteroid-mediated immunoregulation in man. Immunol Rev 1982; 65: 133–155
   PubMed Web of Science ®Google Scholar
• Dale D C, Fauci A S, Wolff S M. Alternate-day prednisone: Leukocyte kinetics and susceptibility to infections. New Engl J Med 1974; 291: 1154–1158
   PubMed Web of Science ®Google Scholar
• Ebert R H, Barclay W R. Changes in connective tissue reaction induced by cortisone. Ann Intern Med 1952; 37: 506–518
   PubMed Web of Science ®Google Scholar
• Martin M M, Gaboardi F, Podolsky S, et al. Intermittent steroid therapy. Its effect on hypothalmic-pituitary-adrenal function and the response of plasma growth hormone and insulin-stimulation. New Engl J Med 1968; 279: 273–278
   PubMed Web of Science ®Google Scholar
• MacGregor R R, Sheagren J N, Lipsett M B, Wolff S M. Alternate day prednisone therapy. Evaluation of delayed hypersensitivity responses, control of disease and steroid side effects. New Engl J Med 1969; 280: 1427–1431
   PubMed Web of Science ®Google Scholar
• Truycotte J G, Haine R F, Brody G L, et al. Immunosuppression by medroxy progesterone acetate. Transplantation 1968; 6: 248–260
   PubMedGoogle Scholar
• Hulka J F, Mohr K, Liberman M W. Effect of synthetic progestational agents on allograft rejection and circulating antibody production. Endrocinology 1965; 77: 897
   PubMed Web of Science ®Google Scholar
• Clemens L E, Siiteri P K, Stites D P. Mechanism of immunosuppression of progesterone on maternal lymphocyte activation during pregnancy. J Immunol 1979; 122: 1978–1985
   PubMed Web of Science ®Google Scholar
• Runnebaum B, Zander J. Progesterone 20 C-dihydroproges-terone and 20 B-dihydroprogesterone in mother and child at birth. Acta Endocrinol 1975; 80: 569–576
   PubMedGoogle Scholar
• Lawrence R, Church J A, Richards W, Borzy M. Immunological mechanisms in the maintenance of pregnancy. Ann Allergy 1980; 44: 166–173
   PubMedGoogle Scholar
• Webel M L, Ritts R E, Taswell H F, et al. Cellular immunity after intravenous administration of methyl prednisolone. J Lab Clin Med 1974; 83: 383–392
   PubMed Web of Science ®Google Scholar
• Isaacs A, Lindenmann J. Virus Interference. I. The Interferon. Proc R Soc London 1957; 147: 258–267
   PubMed Web of Science ®Google Scholar
• Gresser I. Antitumor effects of interferon. Adv Cancer Res 1972; 16: 97–140
   PubMedGoogle Scholar
• Merigan T C, Sikora K, Breeden J H, et al. Preliminary observations on the effect of human leucocyte interferon in non-Hodgkin's lymphoma. New Engl J Med 1978; 299: 1449–1453
   PubMed Web of Science ®Google Scholar
• Braun W, Levy H B. Interferon preparations as modifiers of immune response. Proc Soc Exp Biol Med 1972; 141: 769
   PubMed Web of Science ®Google Scholar
• Epstein L. The effects of interferons on the immune response in vitro and in vivo. Interferons and their Actions, W E Stewart. Chemical Rubber Co, Cleveland 1977; 92–132
   Google Scholar
• Brodeur R B, Merigan T C. Suppressive effect of interferon on the humoral immune response to sheep red blood cells in mice. J Immunol 1974; 113: 1313–1325
   PubMedGoogle Scholar
• Chester T J, Paucker K, Merigan T C. Suppression of mouse antibody producing spleen cells by various interferon preparations. Nature (London) 1973; 246: 92–94
   PubMed Web of Science ®Google Scholar
• Gisler R H, Lindahl P, Gresser I. Effects of interferon on antibody synthesis in vitro. J Immunol 1974; 113: 438–448
   PubMed Web of Science ®Google Scholar
• Pacheco D, Falcoff R, Catktot L, et al. Inhibitory effect of interferon on DNA and RNA synthesis in murine spleen cells stimulated by lectins. Ann Immunol (Inst Pasteur) 1976; 127C: 163–171
   Google Scholar
• Hirsch M S, Ellis D A, Proffitt M R. Effects of interferon on leukaemic virus activation in graft-vs-host disease. Nature (New Biol) 1973; 244: 102–103
   PubMedGoogle Scholar
• Hirsch M S, Ellis D A, Black P H, et al. Immunosuppressive effects of an interferon preparation in vivo. Transplantation 1974; 17: 234–236
   PubMed Web of Science ®Google Scholar
• Jordan G W, Fried R P, Merigan T C. Administration of human leukocyte interferon in herpes zoster. I. Safety, circulating antiviral activity and host response to interferon. J Infect Dis 1974; 130: 56–62
   PubMed Web of Science ®Google Scholar
• Strander H, Cantell K, Carlstrom G, Jakobsson P A. Clinical and laboratory investigations on man: Systemic administration of potent interferon to man. J Natl Cancer Inst 1973; 51: 733–742
   PubMed Web of Science ®Google Scholar
• Djeu J Y, Heinbaugh J A, Holden H T. Augmentation of mouse natural killer cell activity by interferon and interferon inducers. J Immunol 1979; 122: 175–188
   PubMed Web of Science ®Google Scholar
• Gidlund M, Orn A, Wigzell H, et al. Enhanced NK activity in mice injected with interferon inducers. (London) Nature 1978; 273: 759–761
   PubMed Web of Science ®Google Scholar
• Senik A, Gresser I, Maury C, et al. Enhancement by interferon of natural killer cell activity in mice. Cell Immunol 1979; 44: 186–200
   PubMed Web of Science ®Google Scholar
• Zarling J M, Sosman J, Eskra L, et al. Enhancement of T-cell cytotoxic responses by purified human fibroblast interferon. J Immunol 1978; 121: 2002–2004
   PubMed Web of Science ®Google Scholar
• Zarling J M, Eskra L, Borden E C, et al. Activation of human natural killer cells cytotoxic for human leukemia cells by purified interferon. J Immunol 1979; 123: 63
   PubMed Web of Science ®Google Scholar
• Haung K-Y, Donahoe R M, Gordon F B, Dressier H R. Enhancement of phagocytosis by interferon-containing preparations. Infect Immunol 1971; 4: 581–588
   PubMed Web of Science ®Google Scholar
• Schultz R M, Chirigos M A. Similarities among factors that render macrophages tumoricidal in lymphokine and interferon preparations. Cancer Res 1978; 38: 1003–1007
   PubMed Web of Science ®Google Scholar
• Kan-Mitchell J. 1981, unpublished data
   Google Scholar
• Reugger H, Kohn M, Lichti H, et al. Cyclosporin A, Ein Immunsuppressiv wirksamer peptidmetabolite aus trichoderma polysporum [Link ex Pers] rifai. Helv Chim Acta 1976; 59: 1075–1092
   PubMed Web of Science ®Google Scholar
• Borel J F, Feurer C, Gubler H U, Stahelin H. Biological effects of cyclosporin A: A new anti-lymphocytic agent. Agents Actions 1976; 6: 468–475
   PubMedGoogle Scholar
• Calne R Y. The rejection of renal hemografts. Inhibition in dogs by 6-MR Lancet 1960; 1: 417
   PubMed Web of Science ®Google Scholar
• Powles R I, Barrett A J, Clink H. Cyclosporin A for the treatment of graft-vs-host disease in man. Lancet 1978; 2: 1327–1331
   PubMed Web of Science ®Google Scholar
• Hess A D, Donnenberg A D, Tutschka P, Santos J. G. Effect of cyclosporin A on human lymphocyte responses in vitro. V. Analysis of responding T lymphocyte subpopulations in primary MLR with monoclonal antibodies. J Immunol 1983; 130: 717–721
   PubMed Web of Science ®Google Scholar
• Britton S, Palacios R. Cyclosporin A—Usefulness, risks and mechanism of action. Immunol Rev 1982; 65: 5–21
   PubMed Web of Science ®Google Scholar
• Einhorn L H, Williams S D. The role of cis-platinum in solid tumor therapy. New Engl J Med 1979; 300: 289–291
   PubMed Web of Science ®Google Scholar
• Khan A, Hogan S, Hill J M. Immunosuppressive effects of Sulfato-trans-(-)-1, 2-diaminocyclohexaneplatinum (II). Cancer Res 1979; 39: 3476–3478
   PubMed Web of Science ®Google Scholar
• Howie J A, Thompson H S, Stone A E. Cis-dichlordiammine-platinum (II): Inhibition of nucleic acid synthesis in lymphocytes stimulated with phytohemagglutinin. Proc Soc Exp Biol Med 1971; 137: 820–825
   PubMed Web of Science ®Google Scholar
• Wierda D, Pazdernik T L. Suppression of spleen lymphocyte mitogenesis in mice injected with platinum compounds. Eur J Cancer 1979; 15: 1013–1023
   PubMed Web of Science ®Google Scholar
• Kleinerman E S, Zweliing L A, Muchmore A V. The enhancement of naturally occuring spontaneous monocyte-mediated cytotoxicity by cis-diamminedichloroplatinum (II). Cancer Res 1980; 40: 3099–3102
   PubMed Web of Science ®Google Scholar